The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
Structure−Reactivity Correlations in the Dissociative Hydrolysis of 2‘,4‘-Dinitrophenyl 4-Hydroxy-X-benzenesulfonates
作者:Giorgio Cevasco、Sergio Thea
DOI:10.1021/jo961024k
日期:1996.1.1
The hydrolysis reactions of several title esters in water at 60 degrees C follow the rate law k(obs) = (k(a) + k(b)[OH(-)])/(1 + a(H)/K(a)), where K(a) is the ionization constant of the hydroxy group of the ester and k(b) is the second-order rate constant for the S(N)2(S) attack of hydroxide ion on the ionized ester. Hammett and Brønsted correlations are consistent with a previous proposal that the
[EN] INHIBITORS OF ASPARTYL PROTEASE<br/>[FR] INHIBITEURS D'ASPARTYL PROTEASE
申请人:VERTEX PHARMA
公开号:WO2000076961A1
公开(公告)日:2000-12-21
The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.